Sphera Funds Management »

Inhibikase Therapeutics shares owned by Sphera Funds Management

Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by Sphera Funds Management from 13F filings

Historical chart of Sphera Funds Management investment in Inhibikase Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Inhibikase Therapeutics held by Sphera Funds Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibikase Therapeutics by Sphera Funds Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $1.3M 649k 2.03

More positions owned by Sphera Funds Management

Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Biogen Idec (BIIB)
Mineralys Therapeutics (MLYS)
Tower Semiconductor Shs New (TSEM)
Cytokinetics Com New (CYTK)
Spdr Series Trust St Str Sp Biot Put Option (XBI)
Syndax Pharmaceuticals (SNDX)
Ultragenyx Pharmaceutical (RARE)
BioMarin Pharmaceutical (BMRN)
Bridgebio Pharma (BBIO)
Cogent Biosciences (COGT)
NOVA MEASURING Instruments L (NVMI)
Insmed Com Par $.01 (INSM)
Maze Therapeatics (MAZE)
Astrazeneca Ord (AZN)

View all positions for Sphera Funds Management

Top funds holding Inhibikase Therapeutics

Sands Capital Ventures
Soleus Capital Management
Trails Edge Capital Partners
Fairmount Funds Management
BlackRock
ADAR1 Capital Management
Blackstone Group
Siren
Commodore Capital
Vanguard Capital Management
Millennium Management
Saturn V Capital Management
Kalehua Capital Management
Spruce Street Capital
Squadron Capital Management

View all funds holding Inhibikase Therapeutics